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Abstract
One of the greatest challenges in biomedical research, drug discovery and diagnostics is understanding how seemingly
identical cells can respond differently to perturbagens including drugs for disease treatment. Although heterogeneity has
become an accepted characteristic of a population of cells, in drug discovery it is not routinely evaluated or reported. The
standard practice for cell-based, high content assays has been to assume a normal distribution and to report a well-to-well
average value with a standard deviation. To address this important issue we sought to define a method that could be
readily implemented to identify, quantify and characterize heterogeneity in cellular and small organism assays to guide
decisions during drug discovery and experimental cell/tissue profiling. Our study revealed that heterogeneity can be
effectively identified and quantified with three indices that indicate diversity, non-normality and percent outliers. The
indices were evaluated using the induction and inhibition of STAT3 activation in five cell lines where the systems response
including sample preparation and instrument performance were well characterized and controlled. These heterogeneity
indices provide a standardized method that can easily be integrated into small and large scale screening or profiling
projects to guide interpretation of the biology, as well as the development of therapeutics and diagnostics. Understanding
the heterogeneity in the response to perturbagens will become a critical factor in designing strategies for the development
of therapeutics including targeted polypharmacology.
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Introduction
One of the greatest challenges in drug discovery and
development is understanding how seemingly identical cells
respond differently to drug treatment [1]. In cancer, the
prevalence of intra-tumor genetic and phenotypic heterogeneity,
results from clonal evolution [2,3], epigenetic plasticity[4] and
variation in tumor microenvironments [5] and suggest that a single
drug targeting a single driver is not likely to adequately control
disease progression [6]. The complexity of the tumor microenvi-
ronment, which extends to stromal cells, including immune cells,
may contribute significantly to the development of resistance to
treatment [5]. Efforts to recapitulate the in vivo tumor microen-
vironment in physiologically relevant models will require an-
alytical approaches that address the heterogeneity in the model
[7,8]. However, cellular heterogeneity is not limited to cancer cells,
but is exhibited even in normal, clonal cell lines, and the impact of
heterogeneity extends from basic biology to drug discovery and
diagnostics [9–11].
It is now understood that there are multiple sources of
heterogeneity in cell populations including both genetic and
non-genetic factors. Genetic variation is well studied [4,12,13].
Non-genetic heterogeneity, also referred to as phenotypic hetero-
geneity, is variability of one or more phenotypes or traits within a
clonal population [9]. Non-genetic heterogeneity has been
organized into a hierarchy of dichotomies starting with extrinsic
versus intrinsic factors [9]. Variation in extrinsic factors results
from variation in the cellular microenvironment. Intrinsic
heterogeneity arises from intracellular factors, even in a uniform
environment, and can be further subdivided into macro- and
micro-heterogeneity [9]. The former refers to the variability in one
or more cell traits that result in discrete phenotypes and the latter
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to the apparently continuous random variation within a single
phenotype. It is widely accepted that non-genetic heterogeneity
plays an important biological role in cell behaviors such as cell fate
decision in stem cells, development and cellular physiology [9–11].
It is also of increasing interest in tumor diagnostics, therapeutics
and disease management, as well as drug discovery and
development [14–17].
A major opportunity in drug discovery is to apply a quantitative
systems pharmacology (QSP) approach to modulating the
biochemical networks that are involved in disease, in contrast to
identifying and validating a single molecular target up front [18–
20]. High Content Analysis (HCA) [21,22], flow cytometry [23],
single cell genomics [24] and other ‘‘phenotypic’’ methods provide
the capability to measure multiple biomarkers in large numbers of
individual cells. In particular, HCA can be used to profile
individual cells within tissues and small animal models, as well as
in 2D and 3D arrays of cells [15,25]. However, it has been
standard practice in HCA to reduce the detailed cellular data to a
population average (well average) that is intended to characterize
the overall response of the cells, assuming a normal distribution
[26].
The plate-to-plate and the day-to-day variabilities of HCA
measurements are usually characterized by the Z’ factor or the
strictly standardized mean difference (SSMD) [26–29]. These
metrics assume a normal distribution of the well average data [30].
However, there has not been a similar effort in HCA to address
phenotypic heterogeneity in a simple, standard and quantitative
manner amenable to medium to high throughput screening. There
have been multiple studies in which cellular heterogeneity was
evaluated and characterized. For example, classifiers were trained
to identify subpopulations based on collections of phenotypic
features. In some cases the subpopulations were characterized by
the median and interquartile range [31]. In addition, an analysis
based on visual analytics combining parallel-coordinate plots, used
for a visual assessment of the high-dimensional dependencies, and
nonlinear support vector machines, for the quantification of
heterogeneity, has also been demonstrated [32]. A heterogeneity
scoring approach (HetMap) was designed to visualize the
heterogeneity within an individual patient’s breast tissue based
on immunohistochemistry in the context of a patient population
[33]. Furthermore, analytical tools such as Kolmogorov-Smirnov
(KS) statistics, machine learning, and univariate and multivariate
analyses have been applied to analyze perturbations in cells with
drugs and siRNA [34–43]. These analytical tools have been
valuable for characterizing heterogeneity and demonstrating the
value of heterogeneity analysis in drug discovery, pathway analysis
and diagnostics, but are not optimal for routine evaluation of
large-scale screens or profiles.
The goal of the present paper is to describe a method for the
analysis of cellular heterogeneity in cellular phenotypes that
includes: developing a set of ‘‘indices’’ to identify, quantify and
characterize heterogeneity in a way that it can be easily included
in all screening and cellular profiling; as well as to demonstrate an
optimal data representation to visualize the full range of
heterogeneity in the data when it is identified. We use
heterogeneity in the activation of STAT3 as a model system for
developing and testing indices and show how the heterogeneity
indices can be used in high throughput biology and drug discovery
to quantify, compare and flag studies in which: 1) there is a high
degree of variability in the cellular responses, 2) results suggest
there is more than one subpopulation, or 3) there are more than
the expected number of outliers. This important information will
also be essential to interpreting cellular responses in multiplexed,
2D and 3D screens, as well as within more complex microenvi-
ronments in vivo and in vitro, in physiologically relevant disease
and organ models, as well as patient samples.
Materials and Methods
Cell culture
Cal33 human head and neck squamous cell carcinoma
(HNSCC) cells [44,45] were kindly provided by Dr. Gerard
Milano (University of Nice, Nice, France). The cell line was
maintained in Dulbecco’s modified Eagle’s medium (Life Tech-
nologies) supplemented with 10% fetal bovine serum (Gemini Bio-
Products), 100 U/ml penicillin and 100 mg/ml streptomycin
(HyClone). MCF-7 and MDA-MB-468 human breast carcinoma
cells [ATCC cell lines obtained from Dr. Adrian Lee, University of
Pittsburgh] were cultured in DMEM Glutamax media (Life
Technologies) supplemented with 10% FBS (Gemini Bio-Prod-
ucts), 100 U/ml penicillin and 100 mg/ml streptomycin (Hy-
Clone). MCF-10A human breast cells [ATCC cell line obtained
from Dr. Adrian Lee] were cultured in DMEM F12 media (Life
Technologies) supplemented with 5% Horse Serum (Life Tech-
nologies), 10 mg/ml Insulin (Sigma-Aldrich), 20 ng/ml Epidermal
Growth Factor (Sigma-Aldrich), 20 ng/ml Cholera Toxin (Sigma-
Aldrich), 500 ng/ml Hydrocortisone (Sigma-Aldrich), and 1%
Penicillin/Streptomycin (Life Technologies). All cell lines were
maintained in humidified incubators at 37uC with 5% CO2.
Stimulation and inhibition of STAT3 phosphorylation
Cal33 cells were plated in collagen-coated 384-well plates
(Greiner Bio-One) at 2000 cells/well to reach 50% confluence on
the day of fixation. The cells were incubated at 37uC for 24 hours
followed by serum deprivation for another 24 hours. For
stimulation of STAT3 phosphorylation, human recombinant
interleukin-6 (IL-6) and Oncostatin M (OSM) (R&D Systems)
were added in 2-fold or 2.4-fold serial dilution for 10 final
concentrations descending from 200 ng/ml or 50 ng/ml, respec-
tively. For the time course of cellular response to stimulation, the
cells were incubated with cytokines at 37uC for 15, 30, 45, 60 and
120 minutes before fixation. For inhibition of STAT3 phosphor-
ylation, Pyridone-6 (Calbiochem) was added in 10-point 3-fold
serial dilution for final concentrations descending from 5 mM.
Stattic (Sigma-Aldrich) was added in 10-point 3-fold serial dilution
for final concentrations descending from 50 mM. After 3 hours
incubation with the inhibitors at 37uC, cells were stimulated with
50 ng/ml of IL-6 for 15 minutes (peak induction time) before
fixation. Each treatment was performed in triplicate. Each
experiment was repeated at least 3 times. The assays were
optimized for cell density, cytokine dose and treatment time with
their robustness validated using the Z’ factor [27]. Each plate
included 16 positive and 16 negative control wells from which the
Z’ was calculated (ranged from 0.5 to 0.8).
Immunofluorescence labeling
Cells were treated with cytokines with or without incubation
with inhibitors, then fixed in plates for 30 minutes at room
temperature with 3.7% Formaldehyde in PBS, 2 mg/ml Hoechst
33342 (Life Technologies) for nuclear staining, and then
permeabilized on ice with 95% MeOH in PBS for 30 minutes.
Permeabilized cells were washed and incubated with 0.1% Tween-
20 in PBS at 4uC overnight. Cells were labeled for 1 hour with a
1:800 dilution of mouse anti-pY705 STAT3 antibody (BD
Biosciences) followed by a 1 hour incubation with a 1:300 dilution
of the Alexa Fluor 647-donkey anti-mouse AffiniPure secondary
antibody (Jackson ImmunoResearch) prior to high content
Heterogeneity in HCS: Application to Drug Discovery
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imaging. The fixation procedure and antibody titrations were
optimized individually.
High Content Analysis
Labeled cells were imaged with an ArrayScan VTI (Thermo-
Fisher -Cellomics) using a 10X (0.45NA) objective, a stable LED
illumination source with excitations of 386/23 nm and 650/
13 nm, and a multiband emission filter with transmission at 440/
40 nm and 700/60 nm for Hoechst (Ch1) and AlexaFluor 647
(Ch3), respectively. Image correction for non-uniformity of the
field of the VTI was accomplished using an Opera Adjustment
Plate (PerkinElmer) which contains uniform dye solutions as
targets for reference image collection. Images were corrected using
the VTI acquisition software and analyzed using the Compart-
mental Analysis Bioapplication (Thermo Fisher- Cellomics).
Briefly, the Hoechst nuclear images were segmented using an
isodata threshold. The DNA content was measured as the
Bioapplication feature ObjectTotalIntenCh1 for the selected
nuclear region (‘circ’). The ‘circ’ regions were copied to channel
3 where it was used to construct a ‘ring’ starting 1 pixel out from
the ‘circ’ and 3 pixels wide. The STAT3 phosphorylation was
measured using the Bioapplication feature CircRingAvgInten-
DiffCh3. Images of four fields (typically ranges from 2000 to 2500
cells total) were acquired for each well. The pixel average nucleus-
cytoplasm difference (CircRingAvgIntenDiffCh3) in pSTAT3
fluorescence intensity (referred as ‘‘Relative Activity’’ in the plots)
was calculated for each cell in all four fields. Cell level data were
retrieved from the Cellomics Store Database (ThermoFisher) into
Spotfire (TIBCO) using SQL queries and plotted for dose and
time dependent responses. Experimental metadata were merged
into Spotfire using an Excel (Microsoft) template and the
combined data was analyzed to generate a ‘histo-box plot’ as
described below.
Flow Cytometry
Cell and Bead Standards: Flow cytometry standards were used
to establish the resolution and linearity of the high content imaging
relative to that of a flow cytometer. In this study we used Becton
Dickinson 2 mm beads (DNA QC Particles 349523, Becton
Dickinson).
Flow Cytometry: The LSR II (Becton Dickinson) was config-
ured with UV-355 nm, Violet-404 nm, Blue-488 nm and red-633
excitations. The pulse emission areas were collected with the
following filters: Hoechst 33342–450/50 nm, Fluorescein – 530/
30 nm, Cy3 – 610/20 nm, Cy5 – 660/20 nm and Cy7 – 780/
60 nm. To establish that high content imaging was capable of
acquiring accurate DNA histograms, Cal33 cells were run on both
the LSR II flow cytometer and the ArrayScan VTI High Content
imager (ThermoFisher). The cells were trypsinized, fixed, stained
with Hoechst 33342 (Life Technologies) at 2 mg/ml. The flow
cytometry sample was run as a suspension of 26106 cells/ml at a
rate of ,100 cells/sec. The data were then analyzed with FlowJo
7.6.5 (TreeStar) or exported as FCS 3 format for cell cycle analysis
in ModFit (Verity Software House). For high content imaging, the
Cal33 cell suspension was spun down on a 96 well microplate. The
data were exported to text files that were converted to FCS format
with Text to FCS Software 1.2.1 and then analyzed identically to
the flow cytometry data.
Visualization of subpopulation distributions
A modification of a standard ‘box plot’ was generated in
Spotfire to visualize the distributions of cellular responses and
identify heterogeneity in those cell populations. The ‘box’ in a box
plot represents the extent of the central 50% of the population but
gives no indication of the distribution of those values. Spotfire
includes an option in the ‘Appearance’ settings for the box plot to
overlay the distribution (histogram) which we used to create the
visualization we refer to as a ‘histo-box plot’. Similar plots, such as
violin plots [46] and bean plots [47], can be created in R [48],
Matlab (MathWorks) and other applications. The histo-box plot
was used to analyze experimental data from the High Content
Screening assays. Parameters characterizing the distribution such
as the interquartile range (IQR), lower and upper inner fences and
percent outliers were calculated. Log scaling of histo-box plots was
done by applying the ‘Log10’ function in Spotfire to the average
CircRingAvgIntenDiffCh3 values and is referred as ‘Log (Relative
Activity)’ in the plots.
Data analysis
Statistical measures used for heterogeneity analysis:
Coefficient of variation CVð Þ s=m ð1Þ
Interquartile Range IQRð Þ Q3{Q1 ð2Þ




Kolmogorov{Smirnov distance KSð Þ
KS~max jCDFdat{CDFref j
ð4Þ
where s is the standard deviation (SD), m is the mean, Qn is the n-
th quartile, N is the number of data values, d is a linear matrix of
intensity differences between data points i and j, p is the
probability distribution of data points, and CDFdat and CDFref
are the cumulative distribution functions of the data and a
reference distribution, respectively. Quadratic entropy was calcu-
lated as a summation over 64 equally spaced bins spanning the
range from -34 to 1441 to minimize the finite size effects associated
with the binning scheme. Scalar statistic KS values were computed
for each sample distribution using the MATLAB (MathWorks)












with the mean m and standard deviation s of the measured sample
distribution and g is the probability density about x.
Results
Characterization of heterogeneity in HCS
We optimized the assay and performed an HCS screen to
measure the activation of the STAT3 signaling pathway in
response to interleukin 6 (IL-6) and/or Oncostatin M (OSM) using
an antibody against phospho-STAT3-Y705 [49]. The assay was
optimized and validated for timing and duration of activation, as
well as robustness in several cancer and normal cell lines (Figure
S1). The induction of STAT3 by IL-6 in Cal33 cells exhibited a
high level of cell-to-cell variation even at the optimal exposure
time of 15 minutes and a dose that produced maximal activation
Heterogeneity in HCS: Application to Drug Discovery
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($50 ng/ml IL-6). The variability in the fluorescence intensity of
the nuclear localized, activated (phosphorylated) STAT3 was
easily observed in the images (Figure 1A). Despite this cell to cell
heterogeneity within each well, the assay was highly reproducible
by standard criteria (a Z’$0.5, and a signal-to-background .5)
and exhibited a typical dose-response (Figure 1B). However, the
reproducibility indicated in Figure 1B is a measure of the well-to-
well reproducibility and does not give any indication of the cell-to-
cell variability demonstrated by the large error bars (61 SD)
within a well (Figure 1C). Application of standard assay
performance criteria like Z’ to the characterization of cell-to-cell
reproducibility would result in a highly negative Z’, indicating high
cell-to-cell variability, as we observed in Figure 1A and 1C, but no
insight into the nature of the cellular heterogeneity. Clearly a
different approach to characterizing cellular heterogeneity is
needed as a complement to determining the Z’ and S/B for an
assay.
To determine whether the high degree of variation in the level
of STAT3 activation was unique to the Cal33 cell line, and/or
activation by IL-6, we validated the assay on a panel of 5 cell lines
and then compared the activation of STAT3 by 2 different
cytokines, IL-6 and OSM. Figure 2 shows example distributions of
STAT3 activation by 5 doses of IL-6 or OSM in the 5 cell lines
(data provided as DataArchive S1). To visualize the distribution
and statistical parameters of the cellular responses we used a
standard box plot with an overlaid histogram that we refer to as a
‘histo-box plot’ (see Figure S2 for more details). The interquartile
range (IQR, the ‘box’) extends from the 1st quartile to the 3rd
quartile and comprises 50% of the data. The histogram extends
from the lower inner fence (LIF) to the upper inner fence (UIF).
Outliers, points outside the range from LIF to UIF (indicated as
individual points on the plot), as well as reference indicators of the
average (white line) and the 10th and 90th percentiles (black dashed
lines) are presented in the plot. Note that although a standard box
plot indicates the median of the distribution, here for reference we
show the more commonly used assay parameter, the average
value. Clearly the distributions of the activation of STAT3 vary
widely between these cell types, and cytokines.
As illustrated in Figure 2, Cal33 cells exhibit a bimodal
distribution in response to IL-6 and a more ‘‘normal’’ distribution
(though with more outliers) in response to OSM, demonstrating
that different signaling ligands can induce distinct patterns of
heterogeneity in the same cell type. In contrast, 686LN and MCF-
10A cells exhibit a similar distribution of responses to both IL-6
and OSM. The 686LN cells were <4-fold more sensitive to IL-6
and <2-fold less sensitive to OSM than either Cal33 or MCF-10A
cells. The breast cancer cell lines, MCF-7 and MDA-MB-468,
showed little or no response to IL-6, with an apparent dose-
dependent increase in outliers, indicating that a small subset of the
cells respond to IL-6 to the same extent as Cal33 or 686LN cells
and with the same sensitivity as Cal33 cells. The breast cancer cells
exhibit very different responses to OSM. The MDA-MB-468 cells
response to OSM is similar to the MCF-10A cells, while the
majority of MCF-7 cells respond over a range from seemingly non-
responsive to low level responders with outliers exhibiting a high
level response comparable to MCF-10A and MDA-MB-468. In
summary, we observed differences in distributions between cell
lines and between cytokines that varied from narrow to broad,
bimodal vs. normal and variation in the number of outliers. The
presence of macro-heterogeneity, micro-heterogeneity and a
variable % of outliers were evident in these data.
To ensure that the observed heterogeneity was not due to
instrumental or measurement variability (instrument systems
response), we compared HCA measurements of standard fluores-
cent beads and DNA content in Cal33 cells with measurements of
the same samples by flow cytometry (Table S1, Figure S3). In both
cases the imaging CV was 2–3% higher than the flow cytometry
CV, as expected, but still only about 5% for beads and about 8%
for DNA content, well below the CV of < 50% in Figure 1C.
Therefore, instrumental systems response is not an explanation for
the heterogeneity.
In this study, simple biological explanations for the heteroge-
neity observed in Figure 2 could include a dependence on cell
cycle and/or expression level of the IL-6 receptor. We investigated
the potential cell cycle dependence of the activation of STAT3 and
found there was no correlation between cell cycle phase and
STAT3 activation by IL-6 (Figure S4). Western blot analysis of the
expression levels of IL-6 in the cell lines indicates that
responsiveness is not directly correlated with total receptor
expression (Figure S5). Determination of the molecular basis of
Figure 1. Heterogeneity in the activation STAT3 in Cal33 cells. Cal33 cells were treated with IL-6 (50 ng/ml) for 15 min. then fixed and labeled
with an antibody to phospho-STAT3-Y705. A) Pseudocolor image of STAT3 activation shows a high degree of heterogeneity in the intensity of the
Cy5-labeled secondary antibody (color scale at lower right indicates mapping of relative fluorescent intensities to colors). Scale bar is 100 um (lower
left). B) The standard deviation of the well average STAT3 activity in replicate wells (EC50= 3.3 ng/ml, error bars are 61s, N = 8) indicates the assay is
highly reproducible despite the observed cellular heterogeneity (Z’ = 0.54) C) The standard deviation of the cellular STAT3 activity (error bars are61s)
indicates the high variability in the cell-to-cell STAT3 Activity consistent with the appearance of the image (A).
doi:10.1371/journal.pone.0102678.g001
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the heterogeneity is an important challenge and is being pursued
with a range of experimental approaches, including live cell,
kinetic studies of STAT3 activation, but is beyond the scope of this
investigation.
Because the Cal33 cells exhibited a bimodal distribution in
response to IL-6 and a more normal distribution in response to
OSM, we decided to examine those dose-responses in more detail
(Figure 3, DataArchive S1). STAT3 activation by IL-6 in Cal33
cells exhibited a bimodal distribution, with a $10% apparently
non-responding subpopulation at all concentrations tested
(Figure 3A and 3B). For comparison of distributions with different
means, or potentially log-normal distributions [50], we also used a
log-scaled histo-box plot (see Figure S2). Linear scale plots
(Figure 3A & 3C) allow visualization of the intensity range,
separation and size of the subpopulations. When plotted on a log
scale (Figure 3B & 3D), the apparent width of a distribution is
proportional to the linear CV, independent of the mean intensity,
allowing direct comparison of the subpopulation CVs (micro-
heterogeneity). The linear scaled histo-box plot exhibits a narrow
distribution of cells at the unstimulated level of STAT3 intensity
(highlighted in blue), with only a few outliers of activated cells (,
2%). Upon activation with IL-6, there remains a distinct and
persistent subpopulation (<10% at the saturation level of
stimulation-100 ng/ml) of apparently non-responding cells (high-
lighted in blue in Figure 3) and a heterogeneous population of
responding cells. The log scaling (Figure 3B) showed that the CV
of the distribution of the unstimulated cell population is about the
same as that of the stimulated population (58% and 50%
respectively). The presence of the 2 sub-populations, responding
and apparently non-responding is an example of macro-hetero-
geneity. Macro-heterogeneity is distinguished from outliers in that
outliers are singular observations that are well separated from the
median, above the UIF (median +1.5*IPR) or below the LIF
(median – 1.5*IPR), and of insufficient density to be detected
above the background in a histogram. The limits of detecting a
subpopulation will depend on the number and distribution of cells
and may include subpopulation distributions with significant
overlap. Multiplexed assays, looking at multiple parameters will
assist in further defining the sub-populations [31].
Cal33 cells exhibited a different distribution of STAT3
activation in response to OSM. At the OSM saturation
concentration, STAT3 activation was observed in essentially all
the cells (Figure 3). The bimodal distribution was only apparent at
intermediate OSM concentrations (3.62 ng/ml and 8.68 ng/ml)
suggesting two subpopulations of cells, one activated at a lower
dose of OSM, while the other responding at a higher dose, in
contrast to the persistence of the IL-6 resistant subpopulation even
at high doses of IL-6 (Figure 3C and D). Overall, OSM stimulation
of Cal33 cells resulted in a higher degree of activation of STAT3
than stimulation with IL-6. To evaluate whether the cells that do
Figure 2. Variation in the cellular distributions of STAT3 activation by IL-6 and OSM in several cell types. Top series) Histo-box plots of
the activation of STAT3 by IL-6 after 15 min exposure to IL-6 at the indicated concentrations in 2 HNSCC cell lines, 1 breast cell line and 2 breast
cancer cell lines. Bottom series) The activation of STAT3 by OSM was measured at 15 min. in the same 5 cell lines as above. Note: 686LN cells were
found to be much more sensitive to IL-6 and much less sensitive to OSM than the other cell lines, so the concentrations were adjusted appropriately.
doi:10.1371/journal.pone.0102678.g002
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not appear to respond to IL-6 stimulation were in fact capable of
phosphorylating STAT3, we induced cells with combinations of
IL-6 and OSM (Figure S6). Even at the lowest concentration of
OSM tested (2.78 ng/ml) cells co-induced with any concentration
of IL-6 did not exhibit a non-responding subpopulation. Further-
more, at this low concentration of OSM (2.78 ng/ml), OSM alone
did not induce a STAT3 response, suggesting there may be some
cooperativity between IL-6 and OSM activation of STAT3. This
will be investigated in more detail in a future study.
Although the analysis of heterogeneity described above using
the histo-box plot provides insights into functional responses, such
interactive analysis is limited to relatively small numbers of
experiments where throughput is not critical. For large scale
profiling and particularly in compound screening, a method to
identify and quantify heterogeneity is needed in order to compare
large numbers of compounds, targets, or assays and to make
decisions about next steps, efficiently.
Selection and evaluation of the heterogeneity indices
(HI’s)
Based on the results described above we selected properties for
characterization of the distributions that corresponded to the
features that were identified as variable in the histo-box plots and
descriptors that can be interpreted in a biologically meaningful
way. Figure 4 defines the three selected descriptors of the
distributions and the indices selected to quantify those features,
cell diversity (DIV), non-normality (nNRM) and percent outliers
(%OL). We compared the performance of several metrics for
calculating DIV and nNRM, using model distributions and cell
data, and found QE and KS gave the most consistent and robust
results (Figure S7). The indices can be used for relative comparison
or threshold values can be established for classification of samples.
In this assay the Cal33 negative control wells (no IL-6) showed
only a small percentage of cells with activated STAT3 while the
majority were narrowly distributed (Figure 3). We used these
‘homogeneous’ negative control wells to establish a threshold value
for DIV and nNRM, equal to the mean +3*SD of the well-to-well
values of the index. For %OL the threshold was selected based on
a normal distribution. The normal distribution has a UIF-LIF
range of 4 SD (mean 6 2 SD) that contains 95.5% of the
population and therefore the expected %OL is 4.5%. Therefore
the threshold of .4.5% indicates more outliers than would be
expected if the distribution were normal. Figure 5 shows the
application of the selected threshold values for classification of
wells as heterogeneous. To examine the suitability of the candidate
heterogeneity indices and thresholds we used the data sets for IL-6
and OSM induction in the five cell lines (Figure 2). The results are
presented as bar graphs of the three parameters (Figure 6). When
stimulated with IL-6 (left panel), Cal33 cells exhibit a gradual
increase in DIV, a consistently high nNRM and a decrease in
%OL. On the other hand, OSM (right panel) has little effect on
the HI’s below 8.6 ng/ml but induces a nearly 2-fold greater
increase in DIV, with essentially no change in nNRM or %OL,
consistent with the distributions in Figure 3. The other cell lines
exhibit different patterns of response to IL-6 and OSM. 686LN
and MCF-10A cells respond essentially the same to IL-6 and
OSM. MCF-7 and MDA-MB-468 cells respond to IL-6 with an
increase in nNRM and %OL, but no increase in DIV, while OSM
induces a significant increase in DIV, with a small increase in
nNRM in the MCF-7 cells. It is interesting that the pattern of
heterogeneity induced by OSM in MCF-7 cells is very similar to
that induced by IL-6 in Cal33 cells. In nearly all cases OSM
induces a more normally distributed response, which is still
heterogeneous, while the response to IL-6 is much more variable.
The interpretation of the three HI’s is accomplished by applying
a binary decision tree (Figure 5) that classifies a population
distribution as ‘‘homogeneous’’, ‘‘homogeneous with outliers’’,
micro-heterogeneity, micro-heterogeneity with outliers, macro-
heterogeneity, or macro-heterogeneity with outliers. We use
‘‘homogeneous’’ as a relative term, since cell populations always
exhibit some heterogeneity.
We evaluated the effect of two known inhibitors of STAT3
activation on the IL-6 stimulated distributions in Cal33 cells.
Pyridone-6 is a pan-Janus-activated-kinase (Jak) inhibitor [51] and
Stattic is reported to interact with the SH2 domain of STAT3,
inhibiting dimerization and nuclear translocation [52]. Both
compounds inhibited IL-6 induced STAT3 activation with
IC50s of 0.066 mM and 10 mM, respectively (Figure 7 and Figure
S8, DataArchive S2). Figure 7A and 7C display log-scaled histo-
box plots of pyridone-6 and Stattic inhibition of Cal33 cells,
respectively. The IC50s are shown as dashed lines. Pyridone-6
treated samples appear to have an increasing fraction of inhibited
cells starting at the lowest concentration and a stable population of
STAT3 activated cells up to about 0.1 mM, resulting in a
broadening of the distribution. These trends are reflected in the
HI’s (Figure 7B). For pyridone-6 the DIV index is above threshold
up to the IC50, but the increase in the nNRM index indicates the
presence of differentially responding sub-populations of cells,
macro-heterogeneity with outliers. Above 1 mM the cells are
essentially all inhibited, except for a few outliers, some of which
appear to be STAT3 activated cells.
Stattic, in contrast, displayed a stable population distribution
with no evidence of inhibition until the concentration reaches the
IC50 at which point there is a very steep inhibitory effect. Stattic
showed essentially no change in HI’s up to the IC50 indicating
that nearly all the cells have essentially the same sensitivity to this
compound, and therefore respond at the same dose level
(Figure 7D). Thus, while pyridone-6 has a more potent IC50,
Stattic has a more uniform effect as a modulator of STAT3
activation. In both cases the compounds show an increase in %OL
above the IC50, exceeding the selected threshold of 4.5%, and
persisting even at the highest dose tested. This indicates that
neither compound is entirely effective at inhibiting the activation
of STAT3.
An important consideration in the application of the HI’s is the
sample size requirements. To address this we performed power
Figure 3. Visual analysis of phenotypic heterogeneity using the histo-box plot. Population distributions of STAT3 activity in Cal33 cells at
the peak induction time of 15 min. Relative Activity refers to the cell average nuclear intensity of the labeled pSTAT3. Cells with intensity below the
90th percentile of the untreated cells (left most histogram) are colored in blue to highlight the apparently non-responsive subpopulations. ‘‘Count’’
indicates the total number of cells measured. A) Linear-scaled dose-response distributions of STAT3 activity at the indicated concentrations of IL-6
show a persistent subpopulation of cells with a distribution comparable to the unstimulated cells. The well average EC50= 3.3 ng/ml. B) Log-scaling
of the same distributions in A shows that the CV of the responding cells (far right) is similar to the unstimulated cells (far left). C) Linear-scaled
population distributions of STAT3 activation by OSM at the indicated concentrations also show a non-responding subpopulation at 8.68 ng/ml, but
unlike IL-6 there are only a few outliers that are apparently non-responsive at 50 ng/ml and the responding cells appear to be more normally
distributed. D) Log-scaling of the same distributions in C shows that the CV of the responding cells (far right) is similar to the unstimulated cells (far
left).
doi:10.1371/journal.pone.0102678.g003
Heterogeneity in HCS: Application to Drug Discovery
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102678
analysis for the HI’s (Table S2). For the DIV and nNRM indices in
this assay, to achieve a power level of 0.8 requires <900 and
<1100 cells respectively. This number of cells is easily achievable
in standard assay formats such as 384 well microplates. In this
assay, which was implemented in the 384 well format, 1000 cells/
well represents about 4 fields/well at 10x.
Discussion
The significance of heterogeneity in the development of
therapeutics and diagnostics
Heterogeneity is a characteristic of cellular populations that is
fundamental to biological processes including development,
differentiation, and immune-mediated responses [9]. Analysis of
heterogeneity is expected to be useful in a wide range of biological
applications including the differentiation of stem cells and the
development of assays in differentiated neuronal cells, where we
would expect to find significant heterogeneity. Certainly, in the
context of this cancer example, heterogeneity in the response to a
potential therapy is ‘‘bad’’, however, in other applications
heterogeneity analysis may be essential to characterizing the
response of a subpopulation of interest, or even as a primary
readout for screening. When heterogeneity is associated with
dysregulated genetic-based and/or non-genetic-based functions, it
can play a critical role in the progression of complex diseases such
as cancer [53], where intra-tumor heterogeneity poses a formida-
ble challenge to the development of therapeutics [15,54] as well as
diagnostics [15,25,33]. Thus identifying, quantifying and charac-
terizing heterogeneity in patient samples and disease relevant
models for drug discovery using validated cell-by-cell analysis
methods [15,33,53,55] represents an important unmet need. To
address this need we have defined and developed heterogeneity
indices (HI’s) (Figure 4) that enable the full potential of HCA and
other cell-by-cell analytical methods. As a specific example, we
applied these indices to identify, quantify, and characterize
intrinsic heterogeneity in the activation of STAT3 in response to
two cytokines and small molecule perturbagens. Based upon these
results, we recommend a new paradigm for the application of
these or similar HI’s to the discovery of small molecule probes and
therapeutics. Heterogeneity in the response to such probes may
have important implications for understanding fundamental
mechanisms of biological regulation and, as a mainstay in
personalized medicine, lead to the development of novel
therapeutic strategies for complex diseases (see below).
High Content Screening (HCS) was developed as a tool to
automatically acquire, process, store, analyze and view large
amounts of cellular data, creating an efficient platform for cell-by-
cell analysis [22,56–59]. However, the traditional focus in drug
discovery on high throughput screening encouraged most
researchers to focus on well average assays as a standard. This
approach increased the throughput of screening but sacrificed the
information on heterogeneity in the population [30]. As a result,
Figure 4. Three indices for characterizing cellular heterogeneity. Three indices that provide information about the distribution were chosen.
Cell Diversity (DIV) characterizes the overall heterogeneity in the population without regard for the specific shape of the distribution, using the
Quadratic Entropy, a metric that is sensitive to the spread of the distribution as well as the magnitude of the differences between phenotypes in the
distribution. Non-Normality (nNRM) indicates deviation from a normal distribution, distinguishing between micro- and macro-heterogeneity.
%Outliers (%OL) indicates the fraction of cells that respond differently than the majority.
doi:10.1371/journal.pone.0102678.g004
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although heterogeneity is widely recognized as a fundamental
characteristic of biological systems, relatively little is known about
the nature of heterogeneity in the cellular or tissue response to
current pharmaceuticals.
Although a well average assay may exhibit a very good Z’, and
therefore a high degree of reproducibility [27,28], the cell-to-cell
heterogeneity within a well can be significant (Fig 1, 2, 3, 6, 7). In
developing new drugs it is not sufficient to modulate the ‘‘average’’
cell if heterogeneity exists, particularly for cancer therapeutics.
Thus we aimed to identify a simple set of metrics, the HI’s, that
could be automatically calculated and reported along with the
standard well-level read-outs of mean and SD, and the well-to-
well, plate-to-plate and day-to-day metrics of Z’, S/B, and CV, to
rapidly determine if heterogeneity exists and to quantify the extent
of the heterogeneity (Figures 4, 5, 6, 7).
As HCA is utilized more extensively to quantitate cellular
heterogeneity, there must be a focus on the development of quality
control standards and practices such as those that have been
successfully implemented in flow cytometry. To distinguish the
‘‘system’’ variability (includes sample preparation, instrument
response and algorithm performance) from the variability in
biological responses (i.e. intrinsic biological heterogeneity) we used
fluorescent calibration beads with a narrow and well characterized
distribution (Figure S3 and Table S1). These highly uniform beads
established that the minimum limit of variability in measurements
of intensity in this assay, CV of 5–8%, was well below the observed
heterogeneity in STAT3 activation. Minimizing the ‘‘system’’
variability is critical to performing quantitative fluorescence
imaging and has been discussed in detail [60–62].
Selecting heterogeneity indices (HI’s) to apply to single
cell analyses
We considered three properties of the distribution of data that
are significant in the biological interpretation of heterogeneity and
selected HI’s to describe each: 1) How variable is the response? 2)
Is there more than one type of response? and 3) Are there outlier
cells that respond differently? We evaluated several statistical
measures of distribution width (diversity) including the IQR,
Shannon Entropy (SE) [63], Differential Entropy(DE) and
Quadratic Entropy (QE) (see Figure S7). We used the QE, which
has been shown to provide a quantitative measure of species
diversity and incorporates information not only on the number of
different species in a population, but also on the magnitude of the
differences between biological species [64,65]. The QE has also
been shown to be useful in quantitation of the diversity of cellular
phenotypes in cancer tissue sections for diagnostic application
[33], and we have extended that use to the characterization of
cellular diversity (DIV) in HCA assays.
To further characterize the population responses with respect to
the presence of subpopulations (i.e., discrete phenotypic cell states)
we adopted the definition of macro- and micro-heterogeneity
proposed by Huang [9]. Macro-heterogeneity refers to the
variability in one or more cell traits that results in discrete
Figure 5. Decision tree for interpreting the Heterogeneity Indices. Using thresholds established for each index, DIV, nNRM and %OL, a binary
decision tree can be used to characterize heterogeneity in a given sample. The thresholds for DIV (0.03) and nNRM (0.05) were selected as the mean +
3 SD for each index in replicate negative control wells for Cal33 cells. The threshold for %OL (4.5%) is the percent outliers expected for a normal
distribution.
doi:10.1371/journal.pone.0102678.g005
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phenotypes and a multimodal distribution. Examples of macro-
heterogeneity include the distinct states of progenitor vs. differen-
tiated cells, the phases of the cell cycle and the time dependent
changes in the intracellular distribution of proteins such as
transcription factors. Micro-heterogeneity is defined as the
apparently continuous random variation in a single phenotype,
leading to a normal (or log-normal) distribution of the cell trait.
Examples include population noise, such as the prolonged
expression level of a protein during development, and temporal
noise based on stochastic fluctuations of a cell trait within a single
cell over time that are not usually synchronized between cells in
the population.[9]. Based on these definitions, the distinction
between micro- and macro-heterogeneity is equivalent to a
normality test. We evaluated several potential measures of
distribution shape including skewness, kurtosis, mean-median
ratio and the Kolmogorov-Smirnov (KS) test relative to a normal
distribution with the same mean and SD, also known as the
Lilliefors test [66] (see Figure S7). The KS test is an established
measure of normality [67,68] and the use of KS analysis is well
known in HCA [30,35,36,69–71]. The deviation of the distribu-
tion from micro- to macro-heterogeneity, results in an increase in
the KS statistic, which we use as a non-normality index (nNRM),
indicating that there may be more than one mechanism of
response or that the cells may be in more than one state and
therefore should be further evaluated.
The third index of heterogeneity quantifies the percentage of
outliers. The presence of outlier cells that respond distinctly from
the majority is usually completely ignored in HCA. These outliers
may be critically important in the development of therapeutics,
especially in cancer, where a small number of resistant sub-clones
may exist prior to treatment, then undergo positive selection,
resulting in only a transient beneficial response and consequently
result in high rates of relapse [72]. The percent outlier index
(%OL) was chosen based on the standard statistical definition of
outliers used in box plots: samples outside the range from the lower
inner fence to the upper inner fence. Other choices of outlier
definitions could also be applied, but this particular definition is
consistent with our choice of the histo-box plot for reviewing
heterogeneity. The biological interpretation of outliers is chal-
lenging due to the relatively small numbers, but requires further
evaluation when detected.
The combination of these three heterogeneity indices (HI’s) can
be used to classify the heterogeneity in a cell population using a
binary decision tree as shown in Figure 5. The criteria for selecting
classification threshold values will vary depending on the project.
For example, in the IL-6 activation assay, the negative control
Figure 6. Comparison of the activation of STAT3 across 5 cell lines. Application of the HI’s to the data in Figure 2. Left Panel) Activation of
pSTAT3 by exposure to IL-6 for 15 min at the indicated concentrations. Right Panel) Activation of pSTAT3 by exposure to Oncostatin M for 15 min at
the indicated concentrations. Red Bars) Diversity index (DIV) indicating the relative heterogeneity associated with the activation of pSTAT3. The
horizontal red line indicates the selected threshold for classifying populations a heterogeneous. Green Bars) The non-Normality index (nNRM)
indicating the extent of deviation from a single, normally distributed population. The green horizontal line indicates the selected threshold for
classifying a population as having macro-heterogeneity. Blue Bars) The percent outliers (%OL) indicates the percentage of cells with an activity level
that is above the upper inner fence or below the lower inner fence. The horizontal blue line indicates the selected threshold that is used to classify a
population as having more than the expected number of outliers.
doi:10.1371/journal.pone.0102678.g006
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wells were nearly ‘homogeneous’ while in the inhibition assay,
where all wells contained IL-6, the maximally inhibited wells were
most nearly ‘homogeneous’. We chose to use threshold values that
were 3 SD above the mean DIV or nNRM in replicate control
wells as indicating a substantial increase in heterogeneity relative
to the control. Alternatively, for the nNRM index an absolute
threshold could be defined based on the critical values for the KS
test [66,68]. To achieve 99% confidence in the determination of
non-normality, the KS statistic must be $1.031/!N, where N is
the sample size. In this study the minimum sample size was about
2,000 cells per well which results in a critical KS value of 0.02. We
used a more conservative threshold of 0.05. For %OL we defined
an absolute threshold based on the percentage of a normally
distributed population that would be classified as outliers (4.5%).
For screening or other large scale profiling applications, these
indices can be sorted, clustered or viewed as heat maps to identify
Figure 7. Heterogeneity in the response to inhibitors of STAT3 activation. Cal33 cells were exposed to Pyridone-6 (A&B) or STATTIC (C&D)
at the indicated concentrations for 3 hours prior to stimulation with 50 ng/ml of IL-6. A) Inhibition by Pyridone-6. Log scaled distributions are plotted
to normalize CV. B) Three heterogeneity parameters were calculated from the linear scaled data, DIV (red), nNRM (green) and %OL (blue). C) Log
scaled distributions of inhibition by Stattic. D) The same three heterogeneity parameters are plotted for the linear scaled distributions of Stattic
inhibition. The vertical dashed lines indicate the IC50 for the compounds calculated from the well-averaged signal intensities.
doi:10.1371/journal.pone.0102678.g007
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cell population profiles that indicate more complex biology. For
visual analysis of the distribution we found the histo-box plot to be
much more useful than the standard box plot. For multiparameter
assays, the heterogeneity indices can be evaluated on each
readout, or a dimension reduction approach such as principal
component analysis [73,74] can be applied first and the HI’s
calculated for the principal components.
Application and impact of heterogeneity analysis in drug
discovery
For the reasons stated above it is important to apply
heterogeneity analysis throughout the early drug discovery process
from assay design and implementation through secondary screens,
SAR analysis and into pre-clinical studies (Figure 8). The
development of disease relevant models and assays begins with
the analysis of patient samples to identify suitable biomarkers and
assay readouts, and to establish differences in the organization and
heterogeneity profiles of those biomarkers in diseased and normal
tissues. Physiologically relevant models that recapitulate the
disease state may require more complex architecture, including
multiple cell types, which also lead to heterogeneity in assay
readout(s). The methods proposed here can be applied in both
cases to characterize and track heterogeneity, and to optimize the
model. For example, in the Cal33 assay used here, not all of the
cells responded to IL-6 activation of STAT3, whereas all cells
responded to OSM (Figure 3). Choosing IL-6 stimulation for lead
identification may limit the screen to selecting compounds that
have mechanisms present in only a subset of cells (i.e., those that
are IL-6 dependent), ultimately reducing therapeutic efficacy and
necessitating combination strategies (see below). A more appro-
priate assay may be one using OSM and/or a combination of
cytokines as the inducer, but the choice should optimally be driven
by an understanding of the pathway and the role heterogeneity
plays in the dysregulation of STAT3 in cancer tissue.
During implementation of an assay in a screening campaign,
HI’s would be reported alongside the compound potency and
assay performance statistics (Figure 8 and S9), flagging compound
concentrations that exceed the established thresholds (Figure 5). A
DIV that indicates heterogeneity will be an alert that a compound
induced variable responses within the cell population, and the
nNRM and %OL will further classify the heterogeneity. Applying
the decision tree described in Figure 5 to the pyridone-6 data in
Figures 7 and S9, the DIV index indicates heterogeneity below
0.56 mM, while the nNRM index shows a concentration
dependent macro-heterogeneity in the inhibitory response (nNRM
HI.0.05) indicating sub-populations of cells with different
sensitivities to pyridone-6 inhibition. Furthermore, both com-
pounds show an increase in %OL above the IC50, indicating that
some cells continue to activate STAT3, even in the presence of
inhibitor. Although representing only a small percentage of the
cells, resistance to treatment may have important implications in
cancer therapy. The %OL feature should provide additional
information for selection and optimization of hits and leads, as well
as a readout that could be used to screen combinations of
compounds for improved efficacy with respect to outlier cells.
In drug development, compounds where macro-heterogeneity is
identified would need to be further studied, perhaps starting with
the histo-box plot. Compounds exhibiting heterogeneity present
two options: (1) deprioritize in favor of compounds that modulate
the cell population more uniformly; or (2) select the compounds for
efficacy in a specific sub-population for use in a combination
therapy strategy. In this study pyridone-6 and Stattic exhibited
very different, dose dependent heterogeneity profiles, consistent
with their different reported mechanisms of action. The objective
of monitoring heterogeneity in secondary assays should be to
identify potential differences in MOA between lead compounds
and to more fully characterize the range of cellular responses,
enabling more informed decisions in selecting compounds to
advance through drug development.
Finally, it is important to follow the heterogeneity profile while
investigating SAR in the lead optimization stage to ensure that
changes in the compound structure do not introduce additional or
undesirable heterogeneity in the response, implying additional
mechanisms of action. Furthermore, the heterogeneity profile can
be used in combination with biological potency to drive the SAR
of a lead series towards a non-disease profile.
Importance of heterogeneity analysis in understanding
biological regulation and in developing optimized cancer
therapeutic strategies
Darwinian-like clonal evolution significantly contributes to the
genetic heterogeneity within tumors, which contributes to the
observed phenotypic diversity [53,75,76]. Additional intra-tumoral
phenotypic diversity results from epigenetic changes [43,53,75] or
as a consequence of heterotypic signaling within an abnormal
micro-environment [76,77]. This phenotypic diversity and plas-
ticity, in conjunction with the complexity of STAT3 signaling and
regulation that involves crosstalk with several other pathways (e.g.
PI3K, RAS, NFkB, NOTCH) [78–83], enables small molecule
perturbagens to induce both micro- and macro-heterogeneous
responses. For example, fluctuations in the expression of signaling
components can alter the kinetics of a specific step targeted by a
small molecule, inducing micro-heterogeneity. Alternatively mac-
ro-heterogeneity, such as evidenced by the presence of apparently
non-responder subpopulations, could result from changes in
protein expression that result in dysregulation of the crosstalk
involved in negative feedback or the activation of compensatory
pathways. In fact these latter two mechanisms are among the most
common for generating resistance to targeted therapies in cancer
[72,84–87]. Thus, heterogeneity presents a major challenge to
optimizing therapeutic regimens, as the targeting of a predominant
tumor subpopulation often only provides transient benefit and will
inevitably result in the emergence of resistant populations, and
relapse [72].
Recent studies suggest that knowledge of the tumor composition
and the response of component subpopulations to single drugs, in
conjunction with computational and experimental modeling, can
identify drug combinations that minimize the outgrowth of
resistant subpopulations in tumors, while enhancing tumor free
survival in mice [8,88]. Importantly, the experimentally validated
computational simulations demonstrated that the optimal drug
combination predicted depended on whether the entire tumor
population, or only a particular subpopulation, was examined.
These results further emphasize the need to incorporate intra-
tumor heterogeneity and the expected evolutionary trajectories
into rational drug combination design.
The development of comprehensive, unbiased target based
mutagenesis and genome-wide gain- and loss-of-function technol-
ogies that can anticipate clinically relevant resistance, represents
an alternative, or perhaps complementary approach to modeling
and therapeutically addressing tumor heterogeneity [72,90,91]. It
is likely that the future of personalized cancer medicine will involve
a comprehensive bioinformatics analysis of a biopsy that will reveal
the presence of distinct cell populations [6,89] and consultation of
an established drug-genotype database that will allow clinicians to
computationally determine optimal, patient-specific combination
therapies. We hypothesize that heterogeneity analysis will be
essential to the implementation of a QSP-driven approach that
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includes the highly coordinated, parallel optimization of comple-
mentary lead structures, where each structure has a clinically
relevant resistance profile that is addressed by its counterpart,
which will lead to polypharmacologic therapies that effectively
drive the tumor into a state of ‘checkmate’, thereby providing
sustainable remissions and higher cure rates.
Supporting Information
Figure S1 Time course and dose-response of the
activation of STAT3 in Cal33 cells. A) Dose-response of IL-
6 indicated by logistic regression curve fit to well average
intensities in 3 replicate wells. Error bars (61s of the cell-by-cell
Figure 8. Heterogeneity analysis applied throughout the early drug discovery process. Heterogeneity analysis is required to guide
decisions throughout the drug discovery process, beginning with defining disease relevant biology in clinical samples, and establishing benchmarks
for subsequent analyses. Next disease relevant models, which by necessity will be heterogeneous, are developed and optimized. Heterogeneity is
characterized in the models, and thresholds for HI’s are established along with potency criteria to select hits. Screening hits are advanced to
secondary assays based on their potency and HI profile. Heterogeneity of response to compounds will be model dependent, and assessing
heterogeneity in orthogonal secondary assays will provide insights into understanding the MOA. Monitoring the heterogeneity profile during SAR
and lead optimization is essential to keeping lead development on target and mechanism of the disease relevant biology.
doi:10.1371/journal.pone.0102678.g008
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intensities) indicate the high variability in the cell-to-cell STAT3
activity B) Dose-response of OSM activation of STAT3 fit as in A.
Error bars (61s of the cellular intensities) again indicate a high
degree of heterogeneity. C) Well average STAT3 activity in Cal33
cells that were exposed to the indicated concentrations of IL-6 for
the times indicated by color. Error bars (61s of the 3 replicate
wells) indicate the assay is highly reproducible despite cellular
heterogeneity. D) Same as C) except cells were exposed to the
indicated concentrations of OSM. Time indicated by colors.
(TIF)
Figure S2 Use of Histo-Box plot for visualization of
distributions. A) Histograms of simulated, normally distributed
data with the indicated mean and a CV=30% for all unimodal
distributions. The 2 bimodal distributions combine the distribu-
tions with means of 500 and 10 and CV=30%, equally weighted
(‘500+10’) and with a 90:10 split (‘500(90%)+10(10%)’). Each
distribution consists of 2000 random numbers. B) The same
distributions as in A, logarithmically scaled. The key defines the
reference points labeled on the plot (A).
(TIF)
Figure S3 Quantitating the Reproducibility of Intensity
Measurements by Flow and Imaging Cytometry. A)
Histogram of the total intensity of 2 mm flow cytometry standard
beads measured by flow cytometry shows peaks for single beads
(red, CV=2.8) and double beads (blue). B) Histogram of the same
beads centrifuged in the wells of a 384 well microplate and imaged
to measure total bead intensity also shows peaks for single beads
(red, CV=5.2) and double beads (blue). C) The histogram of total
nuclear intensity in Cal33 cells fixed in suspension, labeled with
Hoechst and measured by flow cytometry. Cell cycle modeling
identifies 3 subpopulations, G0/G1 (red), S (hashed), and G2/M
(blue). D) The histogram and cell cycle modeling of the same cells
centrifuged in the wells of a 384 well microplate then imaged and
analyzed for total nuclear intensity.
(TIF)
Figure S4 The distributions of STAT3 activation for cell
cycle subpopulations. Histograms of STAT3 activation in
unstimulated and IL-6 stimulated Cal33 cells (the cell cycle states
identified in the legend). Inset DNA histogram of the cumulative
population shows the mapping of DNA intensities to cell cycle
states.
(TIF)
Figure S5 Western Blot Analysis of Receptor Expres-
sion. A) Western blots of receptor expression in five cell lines, with
Tubulin as a control. B) Quantitation of total density in western
blot bands for the IL-6 receptor, relative to Cal33 cells. C)
Quantitation of OSM receptor expression, relative to Cal33. D)
Quantitation of IFNc receptor expression, relative to Cal33.
(TIF)
Figure S6 STAT3 activation by Combinations of Cyto-
kines. To assess the interaction between the IL-6 and OSM
pathways, Cal33 cells were exposed to combinations of IL-6 and
OSM for 15 min. Top Row) The activation of STAT3 by IL-6
alone. Left Column) The activation of STAT3 by OSM alone.
The arrows point to the location of the population non-responsive
to IL-6. Note that with the addition of OSM all cells treated with
IL-6 show activated STAT3.
(TIF)
Figure S7 Evaluation of Potential indices of Diversity
and Normality. A) Model distributions and cell data were used
to evaluate the performance of selected metrics for characterizing
the distributions. The 50:50 mix consists of 2 unit normal
distributions of equal population that are separated by ‘d’ standard
deviations (sd). The 90:10 mix consists of 2 unit normal
distributions with 90% and 10% of the population, separated by
‘d’ standard deviations. B) Selected Diversity and Normality
indices were used to evaluate the model distributions for values of
‘d’ ranging from 0–10 sd, and the Cal33 data for IL-6 and OSM
stimulation. For the Cal33 data, the diversity indices all show
similar response, while the model data show some key differences.
The IQR (interquartile range) is not sensitive to the small 10%
subpopulation, and the SE (Shannon entropy) and DE (Differen-
tial entropy, the Shannon entropy for a continuous distribution
function) both plateau when the 2 populations separate. Only the
QE (Quadratic entropy) shows a steady increase for both
distributions. Again, the general pattern of the ‘Normality’
measures is similar for the Cal33 data, but the model data show
key differences. The skewness and MMR (mean/median) are
insensitive to the 50:50 population because it is symmetric, The
kurtosis and KS statistic are sensitive to the variation in both
distributions, however the KS was preferred due to its direct
interpretation as a measure of normality.
(TIF)
Figure S8 Dose dependence of inhibitors of STAT3
activation by IL-6. STAT3 activation in Cal33 cells is inhibited
by Pyridone-6 (N) with an IC50= 66 nM or STATTIC (&) with an
IC50 = 10 mM.
(TIF)
Figure S9 Integrating heterogeneity analysis into phe-
notypic screening. Heterogeneity indices are evaluated during
assay development and thresholds determined based on the goals
of the project. For drug discovery and cell/tissue profiling
programs that encounter phenotypic heterogeneity, HCS images
are analyzed to generate the features, statistical parameters and
HI’s. For samples or treatments with low Diversity (DIV) or a
normal distribution (low nNRM) standard statistics can be used. A
well or sample with a high HI and high nNRM or high %OL
would require more detailed analysis of the heterogeneity. If the
observed heterogeneity is biologically important in the context of
the project, further experiments aimed at understanding its
mechanism may lead to discovery of new targets or diagnostic
biomarkers. For pyridone-6, the DIV index for concentrations
below 5 mM indicates a high degree of heterogeneity (HI.0.03
from Figure 5) which is further characterized as macro-
heterogeneity since the nNRM indices are .0.5. At 5 mM the
DIV indicates a homogeneous population with low heterogeneity.
In all cases the %OL is below the HI threshold in Figure 5. The
high heterogeneity indices suggest further studies are needed to
understand the activity of pyridone-6 on these cells.
(TIF)
DataArchive S1 Data for the distribution of STAT3
activation in 5 cell lines stimulated with 10 concentra-
tions of IL-6 or OSM as plotted in Figure 2. Data provided
as a ZIP archive.
(ZIP)
DataArchive S2 Data for the inhibition of IL-6 induced
STAT3 activation by Pyridone-6 and Stattic as plotted in
Figure 7. Data provided as a ZIP archive.
(ZIP)
Table S1 Reproducibility of Intensity Measures. Flow
cytometry standard beads and Cal33 cells were used to quantify
the reproducibility of imaging intensity measurements on cells and
cell sized objects. Samples of beads or cells were split and run on
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either the ArrayScan HCA system or a flow cytometer for
reference. For beads, Ratio is (mean doublet total intensity)/(mean
singlet total intensity). For Cal33 cells, Ratio is (mean G2/M total
nuclear intensity)/(mean G0/G1 total nuclear intensity).
(DOCX)
Table S2 Power analysis of HI measures. Replicate
measures on 3 different days were used to determine the number
of cells required to achieve a power of 0.8 for the CV, KS and QE
measures of the distributions of STAT3 activity in Cal33 cells.
(DOCX)
Acknowledgments
The authors thank the members of their laboratories for fruitful
discussions. The western blot in Figure S5 was prepared with the assistance
of Malabika Sen, Ph.D. Special thanks to Kenneth A. Giuliano, Ph.D.,
who has discussed the importance of heterogeneity with one of us (DLT)
over many years.
Author Contributions
Conceived and designed the experiments: AHG NC TYS TRL RCB CER
JW LAV JRG AVL AMS MES DLT. Performed the experiments: AHG
NC TYS TRL RCB CER JW LAV MES DLT. Analyzed the data: AHG
NC TYS TRL RCB CER JW LAV MES. Contributed reagents/
materials/analysis tools: AHG NC TYS TRL RCB CER JW LAV JRG
AVL AMSMES DLT. Contributed to the writing of the manuscript: AHG
NC TYS TRL RCB CER JW LAV JRG AVL AMS MES DLT.
References
1. Li RX, Zeng R (2009) Dynamic proteomics for investigating the response of
individual cancer cells under drug action. Expert Rev Proteomics 6: 19–21.
2. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481: 306–313.
3. Almendro V, Marusyk A, Polyak K (2013) Cellular Heterogeneity and
Molecular Evolution in Cancer. Annual Review of Pathology: Mechanisms of
Disease 8: 277–302.
4. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell
plasticity. Nature 501: 328–337.
5. Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment
heterogeneity on therapeutic response. Nature 501: 346–354.
6. Fedele C, Tothill RW, McArthur GA (2014) Navigating the challenge of tumor
heterogeneity in cancer therapy. Cancer Discov 4: 146–148.
7. Fang C, Avis I, Salomon D, Cuttitta F (2013) Novel Phenotypic Fluorescent
Three-Dimensional Platforms for High-throughput Drug Screening and
Personalized Chemotherapy. J Cancer 4: 402–415.
8. Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT (2014) Addressing
Genetic Tumor Heterogeneity through Computationally Predictive Combina-
tion Therapy. Cancer Discovery 4: 166–174.
9. Huang S (2009) Non-genetic heterogeneity of cells in development: more than
just noise. Development 136: 3853–3862.
10. Rubin H (1990) The significance of biological heterogeneity. Cancer Metastasis
Rev 9: 1–20.
11. Bright GR, Whitaker JE, Haugland RP, Taylor DL (1989) Heterogeneity of the
changes in cytoplasmic pH upon serum stimulation of quiescent fibroblasts. J Cell
Physiol 141: 410–419.
12. Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and
consequences of genetic heterogeneity in cancer evolution. Nature 501: 338–
345.
13. Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug
resistance. The Lancet Oncology 13: e178–e185.
14. Brock A, Chang H, Huang S (2009) Non-genetic heterogeneity—a mutation-
independent driving force for the somatic evolution of tumours. Nat Rev Genet
10: 336–342.
15. Gough A, Lezon T, Faeder JR, Chennubhotla C, Murphy RF, et al. (2014) High
Content Analysis with Cellular and Tissue Systems Biology: A Bridge Between
Cancer Cell Biology and Tissue-Based Diagnostics. In: Gray J, editor. The
Molecular Basis of Cancer. 4 ed. Philadelphia, PA: Elsevier.
16. Niepel M, Spencer SL, Sorger PK (2009) Non-genetic cell-to-cell variability and
the consequences for pharmacology. Curr Opin Chem Biol 13: 556–561.
17. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, et al.
(2008) Dynamic proteomics of individual cancer cells in response to a drug.
Science 322: 1511–1516.
18. Barabasi AL, Gulbahce N, Loscalzo J (2011) Network medicine: a network-
based approach to human disease. Nat Rev Genet 12: 56–68.
19. Pujol A, Mosca R, Farres J, Aloy P (2010) Unveiling the role of network and
systems biology in drug discovery. Trends Pharmacol Sci 31: 115–123.
20. Auffray C, Chen Z, Hood L (2009) Systems medicine: the future of medical
genomics and healthcare. Genome medicine 1: 2.
21. Taylor DL (2007) Past, present, and future of high content screening and the
field of cellomics. Methods Mol Biol 356: 3–18.
22. Thomas N (2010) High-content screening: a decade of evolution. J Biomol
Screening 15: 1–7.
23. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, et al. (2012)
Multiplexed mass cytometry profiling of cellular states perturbed by small-
molecule regulators. Nat Biotechnol 30: 858–867.
24. Wang D, Bodovitz S (2010) Single cell analysis: the new frontier in ‘omics’.
Trends Biotechnol 28: 281–290.
25. Critchley-Thorne RJ, Miller SM, Taylor DL, Lingle WL (2009) Applications of
Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics.
Combinatorial Chemistry and High Throughput Screening 12: 860–869.
26. Bray MA, Carpenter A (2012) Advanced Assay Development Guidelines for
Image-Based High Content Screening and Analysis. In: Sittampalam GS, Gal-
Edd N, Arkin M, Auld D, Austin C et al., editors. Assay Guidance Manual.
Bethesda (MD): Eli Lilly & Company and the National Center for Advancing
Translational Sciences [Available from: http://www.ncbi.nlm.nih.gov/books/
NBK126174/].
27. Zhang J-H, Chung TDY, Oldenburg KR (1999) A Simple Statistical Parameter
for Use in Evaluation and Validation of High Throughput Screening Assays.
J Biomol Screen 4: 67–73.
28. Zhang XD (2007) A pair of new statistical parameters for quality control in RNA
interference high-throughput screening assays. Genomics 89: 552–561.
29. Azegrouz H, Karemore G, Torres A, Alaiz CM, Gonzalez AM, et al. (2013)
Cell-Based Fuzzy Metrics Enhance High-Content Screening (HCS) Assay
Robustness. J Biomol Screen.
30. Haney SA (2014) Rapid Assessment and Visualization of Normality in High-
Content and Other Cell-Level Data and Its Impact on the Interpretation of
Experimental Results. J Biomol Screen.
31. Loo LH, Lin HJ, Steininger RJ 3rd, Wang Y, Wu LF, et al. (2009) An approach
for extensibly profiling the molecular states of cellular subpopulations. Nat
Methods 6: 759–765.
32. Hasenauer J, Heinrich J, Doszczak M, Scheurich P, Weiskopf D, et al. (2012) A
visual analytics approach for models of heterogeneous cell populations.
EURASIP J Bioinform Syst Biol 2012: 4.
33. Potts SJ, Krueger JS, Landis ND, Eberhard DA, Young GD, et al. (2012)
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer
tissue. Lab Invest 92: 1342–1357.
34. Boland MV, Murphy RF (2001) A neural network classifier capable of
recognizing the patterns of all major subcellular structures in fluorescence
microscope images of HeLa cells. Bioinformatics 17: 1213–1223.
35. Giuliano KA, Chen Y-T, Taylor DL (2004) High-Content Screening with
siRNA Optimizes a Cell Biological Approach to Drug Discovery: Defining the
Role of P53 Activation in the Cellular Response to Anticancer Drugs. J Biomol
Screen 9: 557–568.
36. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, et al. (2004)
Multidimensional drug profiling by automated microscopy. Science 306: 1194–
1198.
37. Giuliano KA, Cheung WS, Curran DP, Day BW, Kassick AJ, et al. (2005)
Systems Cell Biology Knowledge Created from High Content Screening. Assay
Drug Dev Technol 3: 501–514.
38. Loo LH, Wu LF, Altschuler SJ (2007) Image-based multivariate profiling of drug
responses from single cells. Nat Methods 4: 445–453.
39. Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra- and
interline variation following prolonged exposure to antimitotic drugs. Cancer
Cell 14: 111–122.
40. Slack MD, Martinez ED, Wu LF, Altschuler SJ (2008) Characterizing
heterogeneous cellular responses to perturbations. Proceedings of the National
Academy of Sciences of the United States of America 105: 19306–19311.
41. Loo LH, Lin HJ, Singh DK, Lyons KM, Altschuler SJ, et al. (2009)
Heterogeneity in the physiological states and pharmacological responses of
differentiating 3T3-L1 preadipocytes. J Cell Biol 187: 375–384.
42. Singh DK, Ku CJ, Wichaidit C, Steininger RJ 3rd, Wu LF, et al. (2010) Patterns
of basal signaling heterogeneity can distinguish cellular populations with
different drug sensitivities. Mol Syst Biol 6: 369.
43. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic
state transitions give rise to phenotypic equilibrium in populations of cancer
cells. Cell 146: 633–644.
44. Gioanni J, Fischel JL, Lambert JC, Demard F, Mazeau C, et al. (1988) Two new
human tumor cell lines derived from squamous cell carcinomas of the tongue:
establishment, characterization and response to cytotoxic treatment. European
journal of cancer & clinical oncology 24: 1445–1455.
Heterogeneity in HCS: Application to Drug Discovery
PLOS ONE | www.plosone.org 15 July 2014 | Volume 9 | Issue 7 | e102678
45. Bauer VL, Hieber L, Schaeffner Q, Weber J, Braselmann H, et al. (2010)
Establishment and Molecular Cytogenetic Characterization of a Cell Culture
Model of Head and Neck Squamous Cell Carcinoma (HNSCC). Genes 1: 388–
412.
46. Hintze JL, Nelson RD (1998) Violin plots: A box plot-density trace synergism.
American Statistician 52: 181–184.
47. Kampstra P (2008) Beanplot: A Boxplot Alternative for Visual Comparison of
Distributions. Journal of Statistical Software, Code Snippets 28: 1–9.
48. Team RC (2012) R: A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing.
49. Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, et al. (2013) High-Content
pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3
Pathway Activation in Head and Neck Cancer Cell Lines. Assay Drug Dev
Technol.
50. Limpert E, Stahel WA, Abbt M (2001) Log-normal Distributions across the
Sciences: Keys and Clues. Bioscience 51: 341–352.
51. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, et al. (2006)
Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of
multiple myeloma cells. Cancer Res 66: 9714–9721.
52. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule
inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235–1242.
53. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, et al. (2014)
Inference of Tumor Evolution during Chemotherapy by Computational
Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity.
Cell Rep 6: 514–527.
54. Altschuler SJ, Wu LF (2010) Cellular heterogeneity: when do differences make a
difference? Cell 141: 559–563.
55. Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, et al. (2013) Highly
multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer
tissue. Proceedings of the National Academy of Sciences of the United States of
America 110: 11982–11987.
56. Giuliano KA, DeBiasio RL, Dunlay RT, Gough A, Volosky JM, et al. (1997)
High-Content Screening: A New Approach to Easing Key Bottlenecks in the
Drug Discovery Process. J Biomol Screen 2: 249–259.
57. Taylor DL, Haskins JR, Giuliano KA (2007) High content screening : a powerful
approach to systems cell biology and drug discovery. Totowa, N.J.: Humana
Press. xiii, 444 p. p.
58. Haney SA, editor (2008) High Content Screening: Science, Techniques, and
Applications. Hoboken: Wiley.
59. Inglese J, editor (2006) Methods in Enzymology: Vol 414. Measuring Biological
Responses with Automated Microscopy. London: Elsevier.
60. Wang Y-l, Taylor DL, editors (1989) Flourescence Microscopy of Living Cells in
Culture, Part B: Quantitaive Flourescence Microscopy-Imaging and Spectros-
copy. San Diego: Academic Press. 503 p.
61. Wang Y-l, Taylor DL, editors (1988) Flourescence Microscopy of Living Cells in
Culture, Part A: Fluorescent Analogs, Labeling Cells, and Basic Microscopy. San
Diego: Academic Press. 333 p.
62. Chakravarty A, Bowman D, Ecsedy JA, Rabino C, Donovan J, et al. (2007)
Developing Robust High Content Assays. High Content Screening: John Wiley
& Sons, Inc. pp. 85–109.
63. Shannon CE (1948) A Mathematical Theory of Communication. Bell System
Technical Journal 27: 379–423.
64. Rao CR (1982) Diversity and Dissimilarity Coefficients - a Unified Approach.
Theor Popul Biol 21: 24–43.
65. Schleuter D, Daufresne M, Massol F, Argillier C (2010) A User’s Guide to
Functional Diversity Indices. Ecol Monogr 80: 15.
66. Lilliefors HW (1967) On the Kolmogorov-Smirnov Test for Normality with
Mean and Variance Unknown. J Am Stat Assoc 62: 399–402.
67. Razali NM, Wah YB (2011) Power Comparisons of Shapiro-Wilk, Kolmogorov-
Smirnov, Lilliefors and Anderson-Darling Tests. Journal of Statistical Modeling
and Analytics 2: 13.
68. Ong LD, LeClare PC (1968) The Kolmogorov-Smirnov test for the log-
normality of sample cumulative frequency distributions. Health Phys 14: 376.
69. Young IT (1977) Proof without prejudice: use of the Kolmogorov-Smirnov test
for the analysis of histograms from flow systems and other sources. J Histochem
Cytochem 25: 935–941.
70. Huang S (2010) Statistical issues in subpopulation analysis of high content
imaging data. J Comput Biol 17: 879–894.
71. Ng AY, Rajapakse JC, Welsch RE, Matsudaira PT, Horodincu V, et al. (2010) A
cell profiling framework for modeling drug responses from HCS imaging.
J Biomol Screen 15: 858–868.
72. Garraway LA, Janne PA (2012) Circumventing cancer drug resistance in the era
of personalized medicine. Cancer Discov 2: 214–226.
73. Sexton JZ, He Q, Forsberg LJ, Brenman JE (2010) High content screening for
non-classical peroxisome proliferators. International journal of high throughput
screening 2010: 127–140.
74. Abraham Y, Zhang X, Parker CN (2014) Multiparametric Analysis of Screening
Data: Growing Beyond the Single Dimension to Infinity and Beyond. J Biomol
Screen.
75. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking
glass for cancer? Nat Rev Cancer 12: 323–334.
76. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
77. Li HJ, Reinhardt F, Herschman HR, Weinberg RA (2012) Cancer-stimulated
mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2
signaling. Cancer discovery 2: 840–855.
78. Johnston PA, Grandis JR (2011) STAT3 SIGNALING: Anticancer Strategies
and Challenges. Mol Interv 11: 18–26.
79. Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, et al. (2004)
Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT
signalling. Nat Cell Biol 6: 547–554.
80. Raj A, van Oudenaarden A (2008) Nature, nurture, or chance: stochastic gene
expression and its consequences. Cell 135: 216–226.
81. Bollrath J, Greten FR (2009) IKK/NF-kappaB and STAT3 pathways: central
signalling hubs in inflammation-mediated tumour promotion and metastasis.
EMBO Rep 10: 1314–1319.
82. Vogt PK, Hart JR (2011) PI3K and STAT3: a new alliance. Cancer Discov 1:
481–486.
83. Leslie K, Gao SP, Berishaj M, Podsypanina K, Ho H, et al. (2010) Differential
interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-
induced transformation. Breast Cancer Res 12: R80.
84. Engelman JA, Janne PA (2008) Mechanisms of acquired resistance to epidermal
growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for
Cancer Research 14: 2895–2899.
85. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway
reactivation. Nature 468: 968–972.
86. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo
O, et al. (2011) AKT inhibition relieves feedback suppression of receptor
tyrosine kinase expression and activity. Cancer Cell 19: 58–71.
87. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, et al. (2009) Basal
subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback
signaling determine susceptibility of breast cancer cells to MEK inhibition.
Cancer Res 69: 565–572.
88. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, et al.
(2013) Defining principles of combination drug mechanisms of action.
Proceedings of the National Academy of Sciences of the United States of
America 110: E170–179.
89. Beckman RA, Schemmann GS, Yeang CH (2012) Impact of genetic dynamics
and single-cell heterogeneity on development of nonstandard personalized
medicine strategies for cancer. Proceedings of the National Academy of Sciences
of the United States of America 109: 14586–14591.
90. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-
571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831–
843.
91. Wood KC, Konieczkowski DJ, Johannessen CM, Boehm JS, Tamayo P, et al.
(2012) MicroSCALE screening reveals genetic modifiers of therapeutic response
in melanoma. Sci Signal 5: rs4.
Heterogeneity in HCS: Application to Drug Discovery
PLOS ONE | www.plosone.org 16 July 2014 | Volume 9 | Issue 7 | e102678
